Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Ottawa

$25,000.00

Tracking the fate of novel bioparticles in vivo

FY 2016-17

Summary
Qu Biologics is a privately held clinical-stage biotechnology company operating out of Vancouver, BritishColumbia. Qu Biologics has an innovative platform of Site Specific Immunomodulators, which are biologicallyderived particulate materials that can mobilize and correct dysfunction in the innate immune system thatcontribute to disease, including cancer and irritable bowel disease. The fundamental knowledge of how theseSSI interact with tissues of the body, especially after repeated exposure, is not fully understood. However, QuBiologics requires the complete characterization of the fundamental behaviour of their SSI to fully exploit thepotential of this novel therapeutic. In order to provide this information, the SSI will be chemically modified fortwo purposes. First, they will be modified to allow them to be tracked in live subjects so the fate of thistherapeutic can be evaluated. Second, they will be modified so that the SSI can be specifically extracted fromthe body and their integrity can be determined over time using high resolution microscopy techniques. Overall,the proposed work will provide new techniques and new understanding of SSI technology, which will allow QuBiologics to improve product composition, optimize delivery strategies, and understand the behaviour of futureiterations of SSI in living subjects.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
507652-2016
Name nom
Shuhendler, Adam
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
2006
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Biomaterials
Research subject fr
Biomatériaux
Partie
1
Nb partie
1
Application title
Tracking the fate of novel bioparticles in vivo
Keyword
NSERC
Application summary
Qu Biologics is a privately held clinical-stage biotechnology company operating out of Vancouver, BritishColumbia. Qu Biologics has an innovative platform of Site Specific Immunomodulators, which are biologicallyderived particulate materials that can mobilize and correct dysfunction in the innate immune system thatcontribute to disease, including cancer and irritable bowel disease. The fundamental knowledge of how theseSSI interact with tissues of the body, especially after repeated exposure, is not fully understood. However, QuBiologics requires the complete characterization of the fundamental behaviour of their SSI to fully exploit thepotential of this novel therapeutic. In order to provide this information, the SSI will be chemically modified fortwo purposes. First, they will be modified to allow them to be tracked in live subjects so the fate of thistherapeutic can be evaluated. Second, they will be modified so that the SSI can be specifically extracted fromthe body and their integrity can be determined over time using high resolution microscopy techniques. Overall,the proposed work will provide new techniques and new understanding of SSI technology, which will allow QuBiologics to improve product composition, optimize delivery strategies, and understand the behaviour of futureiterations of SSI in living subjects.